← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

Cardiovascular Risk in Diabetes: Evidence and Outcomes

Evidence related to cardiovascular risk, cardiovascular events, ASCVD risk, vascular function, functional capacity, and mortality outcomes in diabetes studies.

Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/cardiovascular-risk

Executive Summary

Cardiovascular Risk evidence appears to center on Semaglutide.

Among 44 indexed studies and 38 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Evidence Snapshot

Studies analyzed
44
Evidence relationships
67
Interventions
38
Outcomes
14
Strong evidence signals
1
Mixed evidence areas
0

Key Findings

  1. 01

    Across 7 studies, Semaglutide shows a strong positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

  2. 02

    Across 6 studies, Semaglutide shows a evidence signal for All-cause mortality.

  3. 03

    Across 4 studies, Semaglutide shows a evidence signal for Nonfatal stroke.

  4. 04

    Across 3 studies, Semaglutide shows a consistent strong positive signal for Cardiovascular events.

Question Highlights

What improves cardiovascular risk?

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for Cardiovascular Risk.

Semaglutide, Finerenone (nonsteroidal mineralocorticoid receptor antagonist), and SGLT2 inhibitors are among the best-supported options in the available evidence across 44 studies.

Consistency cannot yet be determined.

Read the full answer

Does Semaglutide improve cardiovascular risk?

Semaglutide appears to improve Cardiovascular events.

Strong evidence is based on 10 supporting studies.

The evidence includes both beneficial and harmful or worsening results.

Read the full answer

How can I lower cardiovascular events?

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for Cardiovascular events.

Emerging evidence is based on 6 supporting studies.

Consistency cannot yet be determined.

Read the full answer

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

Evidence is consistently positive across multiple studies.

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Semaglutide appears to have a consistent beneficial signal in the indexed evidence.

Leading examples

Semaglutide · Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

Evidence basis: 13 evidence pairs - 13 studies

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Semaglutide is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

Semaglutide · Intensive glycemic control · Liraglutide

Evidence basis: 21 evidence pairs - 16 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) · SGLT2 inhibitors · Berberine

Evidence basis: 15 evidence pairs - 8 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—